system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: 9,10-Dimethyl-1,2-benzanthracene, Blotting, Western, Carcinogenesis, Carcinoma, Squamous Cell, Epithelial Cells, Epithelial-Mesenchymal Transition, Female, Gene Expression Regulation, Neoplastic, Gingiva, Humans, Immunohistochemistry, In Vitro Techniques, Male, Middle Aged, Mouth Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Serine-Arginine Splicing Factors.
user
Is expression of SRSF3 Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma? Context: Oral squamous cell carcinoma (OSCC) is the most common malignancy of head and neck with high mortality rates. The mechanisms of initiation and development of OSCC remain largely unknown. Dysregulated alternative splicing of pre-mRNA has been associated with OSCC. Splicing factor SRSF3 is a proto-oncogene and overexpressed in multiple cancers. The aim of this study was to uncover the relationship between SRSF3 and carcinogenesis and progression of oral squamous cell carcinoma. The expression of SRSF3 in oral normal, dysplasia, or carcinoma tissues was analyzed by immunohistochemistry. The expression levels of EMT-related genes were quantified by real-time quantitative RT-PCR. The expression of SRSF3 in DMBA treated primary cultured oral epithelial cells were analyzed by western blot. SRSF3 is overexpressed in oral cancer and moderate or severe dysplasia tissues. Patients with high grade cancer or lymphatic metastasis showed up-regulated expression of SRSF3. Knockdown of SRSF3 repressed the expression of Snail and N-cadherin in vitro. Carcinogen DMBA treated primary cultured oral epithelial cells showed significantly increased SRSF3 level than in control cells.
assistant
Our results suggested that SRSF3 is associated with the initiation and development of OSCC and may be a biomarker and therapeutic target of OSCC. Final Decision: yes